GRNOPC1: Interim Phase I data

Interim data from an ongoing, open-label, U.S. Phase I trial showed that GRNOPC1 injected 7-14 days post-injury led to no adverse events in 2 patients with neurologically complete thoracic SCIs. One patient has completed the 180 day follow-up, while the second patient has completed the 7 day follow-up. The trial is expected to enroll up to 10 patients and may be expanded to include patients with neurologically incomplete injuries and cervical spinal cord injuries. Data were presented at the International Conference on Spinal Cord Medicine and Rehabilitation in Washington. ...